饲料销量增速放缓 天康生物2024年靠生猪养殖逆势翻盘

Core Insights - TianKang Biological (002100.SZ) reported a mixed performance in 2024, with revenue declining by 9.72% to 17.176 billion yuan, while net profit surged by 144.38% to 605 million yuan, reflecting a strategic shift in business focus amidst industry challenges [2][3] Revenue Breakdown - The feed business, a traditional pillar for TianKang, saw sales revenue drop by 17.67% to 5.345 billion yuan, accounting for 31.12% of total revenue, primarily due to weakened demand from the livestock sector and increased raw material price volatility [2] - In contrast, the pig farming and food processing segment became the largest revenue contributor with sales of 6.157 billion yuan, achieving an 11.11% year-on-year growth, driven by improved production efficiency and rising pig prices [3] Operational Efficiency - TianKang's pig farming segment achieved a record high gross margin in nearly four years, with a total of 3.0285 million pigs sold and a reduction in production costs from 15.99 yuan/kg at the beginning of the year to 13.12 yuan/kg by year-end, showcasing effective cost management [3] Strategic Initiatives - The company is exploring collaborative solutions across its supply chain, emphasizing the integration of feed, vaccines, and farming services to provide comprehensive support for livestock farmers [3]